Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart's Pre-clinical Data Reveals Potential Of Mucosal Vaccine Platform For HPV- Cervical Dysplasia
Vaxart Dips on Test Results
Express News | Vaxart- Co's Hpv Vaccine Constructs Can Stimulate Potent Immune Response Against Hpv16 Proteins E6 & E7
Express News | Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia
Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia